諾泰生物(688076.SH):注射用胸腺法新(1.6mg)擬中標第五批國家組織藥品集採
格隆匯6月23日丨諾泰生物(688076.SH)公佈,公司參加了聯合採購辦公室組織的第五批國家組織藥品集中採購的投標工作。公司的注射用胸腺法新(1.6mg)中標此次集中採購。擬中標價格31.76元/盒。
按照聯採辦發佈的《全國藥品集中採購文件(GY-YD2021-2)》相關規定,採購週期為3年。採購週期內採購協議每年一簽,續簽採購協議時,約定採購量原則上不少於各地該中選藥品上年約定採購量。
公司擬中標的注射用胸腺法新於2021年1月獲得國家藥品監督管理局簽發的《藥品補充申請批准通知書》(通知書編號:2021B00155),截至2020年12月31日實現銷售收入793.30萬元,佔公司2020年度營業收入的比例為1.40%。
此次集中採購是第五批國家組織藥品集中採購,採購週期中,醫療機構將優先使用本次藥品集中採購中選藥品,並確保完成約定採購量。若公司後續簽訂採購合同並實施後,將有利於進一步擴大該產品的銷售規模,擴充合作渠道,提高市場佔有率,促進公司相關產品國內市場的開拓,提升公司的品牌影響力,對公司的未來經營業績產生積極的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.